These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 27357182)

  • 1. Anagliptin, A Dipeptidyl Peptidase-4 Inhibitor Ameliorates Arterial Stiffness in Association with Reduction of Remnant-Like Particle Cholesterol and Alanine Transaminase Levels in Type 2 Diabetic Patients.
    Tahara N; Yamagishi SI; Bekki M; Kodama N; Nakamura T; Sugiyama Y; Oshige T; Kumashiro Y; Honda A; Tahara A; Igata S; Fukumoto Y
    Curr Vasc Pharmacol; 2016; 14(6):552-562. PubMed ID: 27357182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study.
    Bekki M; Tahara N; Tahara A; Igata S; Honda A; Sugiyama Y; Nakamura T; Sun J; Kumashiro Y; Matsui T; Fukumoto Y; Yamagishi SI
    Curr Vasc Pharmacol; 2019; 17(4):411-420. PubMed ID: 29766812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial.
    Ueda S; Shimabukuro M; Arasaki O; Node K; Nomiyama T; Morimoto T
    Cardiovasc Drugs Ther; 2018 Feb; 32(1):73-80. PubMed ID: 29435776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy.
    Furuhashi M; Sakuma I; Morimoto T; Higashiura Y; Sakai A; Matsumoto M; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Node K; Ueda S
    Cardiovasc Diabetol; 2020 Jun; 19(1):89. PubMed ID: 32539832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy.
    Furuhashi M; Sakuma I; Morimoto T; Higashiura Y; Sakai A; Matsumoto M; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Node K; Ueda S
    J Atheroscler Thromb; 2022 Jan; 29(1):24-37. PubMed ID: 33342939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients with type 2 diabetes: A randomized controlled trial.
    Onoue T; Goto M; Wada E; Furukawa M; Okuji T; Okada N; Kobayashi T; Iwama S; Sugiyama M; Tsunekawa T; Takagi H; Hagiwara D; Ito Y; Morishita Y; Seino Y; Suga H; Banno R; Hamada Y; Ando M; Yamamori E; Arima H
    PLoS One; 2020; 15(1):e0228004. PubMed ID: 31990936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of glycemic control with sitagliptin on the 2-year progression of arterial stiffness: a sub-analysis of the PROLOGUE study.
    Tomiyama H; Miwa T; Kan K; Matsuhisa M; Kamiya H; Nanasato M; Kitano T; Sano H; Ohno J; Iida M; Sata M; Yamada H; Maemura K; Tanaka A; Murohara T; Node K
    Cardiovasc Diabetol; 2016 Nov; 15(1):150. PubMed ID: 27809848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.
    Jax T; Stirban A; Terjung A; Esmaeili H; Berk A; Thiemann S; Chilton R; von Eynatten M; Marx N
    Cardiovasc Diabetol; 2017 Jan; 16(1):13. PubMed ID: 28109295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bezafibrate Ameliorates Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Hypertriglyceridemic Patients with Type 2 Diabetes Mellitus.
    Yamaguchi T; Shirai K; Nagayama D; Nakamura S; Oka R; Tanaka S; Watanabe Y; Imamura H; Sato Y; Kawana H; Ohira M; Saiki A; Shimizu N; Tatsuno I
    J Atheroscler Thromb; 2019 Jul; 26(7):659-669. PubMed ID: 30584220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial.
    Chihara A; Tanaka A; Morimoto T; Sakuma M; Shimabukuro M; Nomiyama T; Arasaki O; Ueda S; Node K
    Cardiovasc Diabetol; 2019 Nov; 18(1):158. PubMed ID: 31733647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®).
    Marx N; Rosenstock J; Kahn SE; Zinman B; Kastelein JJ; Lachin JM; Espeland MA; Bluhmki E; Mattheus M; Ryckaert B; Patel S; Johansen OE; Woerle HJ
    Diab Vasc Dis Res; 2015 May; 12(3):164-74. PubMed ID: 25780262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DPP-4 inhibitor treatment: β-cell response but not HbA
    Kozlovski P; Bhosekar V; Foley JE
    Vasc Health Risk Manag; 2017; 13():123-126. PubMed ID: 28408838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anagliptin decreases serum lathosterol level in patients with type 2 diabetes: a pilot study.
    Aoki K; Ijima T; Kamiyama H; Kamiko K; Terauchi Y
    Expert Opin Pharmacother; 2015; 16(12):1749-54. PubMed ID: 26098722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of lipid-lowering action of the dipeptidyl peptidase-4 inhibitor, anagliptin, in low-density lipoprotein receptor-deficient mice.
    Yano W; Inoue N; Ito S; Itou T; Yasumura M; Yoshinaka Y; Hagita S; Goto M; Nakagawa T; Inoue K; Tanabe S; Kaku K
    J Diabetes Investig; 2017 Mar; 8(2):155-160. PubMed ID: 27860391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study).
    Ahn CH; Han KA; Yu JM; Nam JY; Ahn KJ; Oh TK; Lee HW; Lee DH; Kim J; Chung CH; Park TS; Kim BJ; Park SW; Park HK; Lee KJ; Kim SW; Park JH; Ko KP; Kim CH; Lee H; Jang HC; Park KS
    Diabetes Obes Metab; 2017 May; 19(5):635-643. PubMed ID: 28026912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of anagliptin, a dipeptidyl peptidase-4 inhibitor, in managing type 2 diabetes: A systematic review and meta-analysis.
    Kamrul-Hasan ABM; Dutta D; Nagendra L; Sharma M; Patra S; Bhattacharya S
    Medicine (Baltimore); 2024 Jul; 103(28):e38870. PubMed ID: 38996148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the Dipeptidyl Peptidase 4 Inhibitor Alogliptin on Blood Pressure in Hypertensive Patients with Type 2 Diabetes Mellitus.
    Kishimoto S; Kinoshita Y; Matsumoto T; Maruhashi T; Kajikawa M; Matsui S; Hashimoto H; Takaeko Y; Kihara Y; Chayama K; Goto C; Mohamad Yusoff F; Nakashima A; Noma K; Higashi Y
    Am J Hypertens; 2019 Jun; 32(7):695-702. PubMed ID: 31045223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study.
    Hiruma S; Shigiyama F; Hisatake S; Mizumura S; Shiraga N; Hori M; Ikeda T; Hirose T; Kumashiro N
    Cardiovasc Diabetol; 2021 Feb; 20(1):32. PubMed ID: 33530982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anagliptin, a dipeptidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterol-fed rabbits.
    Hirano T; Yamashita S; Takahashi M; Hashimoto H; Mori Y; Goto M
    Metabolism; 2016 Jun; 65(6):893-903. PubMed ID: 27173468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does the treatment of type 2 diabetes mellitus with the DPP-4 inhibitor vildagliptin reduce HbA1c to a greater extent in Japanese patients than in Caucasian patients?
    Foley JE; Bhosekar V; Kawamori R
    Vasc Health Risk Manag; 2016; 12():9-12. PubMed ID: 26855580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.